Ma Jennifer, Setton Jeremy, Morris Luc, Albornoz Pedro Blecua Carrillo, Barker Christopher, Lok Benjamin H, Sherman Eric, Katabi Nora, Beal Kathryn, Ganly Ian, Powell Simon N, Lee Nancy, Chan Timothy A, Riaz Nadeem
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Oncotarget. 2017 Feb 7;8(6):10312-10323. doi: 10.18632/oncotarget.14400.
Radiation therapy is a mainstay of cancer treatment, yet the molecular determinants of clinical response are poorly understood. We identified exceptional responders to radiotherapy based on clinical response, and investigated the associated tumor sequencing data in order to identify additional patients with similar mutations. Among head and neck squamous cell cancer patients receiving palliative radiotherapy at our institution, we identified one patient with documented complete metabolic response. Targeted sequencing analysis of the tumor identified a somatic frame-shift mutation in ATM, a gene known to be associated with radio-sensitivity in the germline. To validate the association of somatic ATM mutation with radiotherapy response, we identified eight patients with ATM truncating mutations who received radiotherapy, all of whom demonstrated excellent responses with a median local control period of 4.62 years. Analysis of 22 DNA repair genes in The Cancer Genome Atlas (TCGA) data revealed mutations in 15.9% of 9064 tumors across 24 cancer types, with ATM mutations being the most prevalent. This is the first study to suggest that exceptional responses to radiotherapy may be determined by mutations in DNA repair genes. Sequencing of DNA repair genes merits attention in larger cohorts and may have significant implications for the personalization of radiotherapy.
放射治疗是癌症治疗的主要手段,但对临床反应的分子决定因素了解甚少。我们根据临床反应确定了放射治疗的特殊反应者,并研究了相关的肿瘤测序数据,以识别更多具有相似突变的患者。在我们机构接受姑息性放射治疗的头颈部鳞状细胞癌患者中,我们发现了一名有记录的完全代谢反应患者。对该肿瘤进行的靶向测序分析发现ATM基因存在体细胞移码突变,该基因在种系中已知与放射敏感性相关。为了验证体细胞ATM突变与放射治疗反应的关联,我们确定了8名接受放射治疗的ATM截短突变患者,他们均表现出良好的反应,中位局部控制期为4.62年。对癌症基因组图谱(TCGA)数据中22个DNA修复基因的分析显示,在24种癌症类型的9064个肿瘤中,15.9%存在突变,其中ATM突变最为常见。这是第一项表明对放射治疗的特殊反应可能由DNA修复基因突变决定的研究。对DNA修复基因进行测序在更大的队列中值得关注,可能对放射治疗的个性化具有重要意义。